View an enhanced version of the report summarizing our financial and
operational performance for the past year.
View the enhanced document outlining key information
about the upcoming shareholder meeting.
Request paper copies of the above proxy materials online now, by email
or by phone by dialing 866-648-8133.
Your vote is important! Please be sure to vote your shares online now or by phone by dialing 866-305-2950.
We are a biopharmaceutical company focused on discovering and developing small molecule kinase inhibitors to address existing and emerging unmet needs in oncology. With a precision oncology approach, our aim is to improve survival and enhance overall well-being for cancer patients.